Shares of Amicus Therapeutics dropped 5.59% to $9.70 at 16:19 EST on Tuesday, following the last session’s upward trend. NASDAQ Composite is dropping 2.31% to $13,574.72, after two successive sessions in a row of losses. This seems, as yet, an all-around rough trend exchanging session today.

Amicus Therapeutics’s last close was $10.28, 161.75% under its 52-week high of $25.39.

Amicus Therapeutics’s Sales

Amicus Therapeutics’s sales growth is 18.4% for the present quarter and 20.6% for the next. The company’s growth estimates for the present quarter is 31.4% and a drop 10% for the next.

Amicus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 27.6%, now sitting on 260.89M for the twelve trailing months.

Amicus Therapeutics’s Stock Yearly Top and Bottom Value

Amicus Therapeutics’s stock is valued at $9.70 at 16:19 EST, way below its 52-week high of $25.39 and higher than its 52-week low of $8.83.

Amicus Therapeutics’s Moving Average

Amicus Therapeutics’s worth is under its 50-day moving average of $10.76 and way below its 200-day moving average of $17.69.

More news about Amicus Therapeutics.


Please enter your comment!
Please enter your name here